<SEC-DOCUMENT>0001437749-21-006941.txt : 20210324
<SEC-HEADER>0001437749-21-006941.hdr.sgml : 20210324
<ACCEPTANCE-DATETIME>20210324073121
ACCESSION NUMBER:		0001437749-21-006941
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210324
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210324
DATE AS OF CHANGE:		20210324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		21766630

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20210312b_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20210324"><head><!--Created on 3/12/2021 6:59:53 AM -->
	<title>mbrx20210312b_8k.htm</title>


<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20218K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20218K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20210324.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20218K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-03-24</xbrli:startDate>
<xbrli:endDate>2021-03-24</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>FORM <ix:nonNumeric contextRef="d20218K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20218K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>March 24, 2021</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="moleculin-logo_horizresizedf.jpg" src="moleculin-logo_horizresizedf.jpg" /></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:15.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">Delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:15.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:15.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</div>
			</td>
			<td style="vertical-align:top;width:15.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:15.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive</b></ix:nonNumeric><b>, Suite 950, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(<ix:nonNumeric contextRef="d20218K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20218K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:45.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric>&#xa0;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:45.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric>&#xa0;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:45.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:45.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:Security12bTitle">Common Stock, par value $.001 per share</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Stock Market LLC</ix:nonNumeric></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On March 24, 2021, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2020 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No. </b></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_233629.htm" style="-sec-extract:exhibit;">99.1</a></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_233629.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Press Release dated March 24, 2021</span></a></div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 24, 2021</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <span style="text-decoration: underline;">/s/ Jonathan P. Foster</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:22.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jonathan P. Foster</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">2</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EXHIBIT INDEX</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline;">Exhibit </span></b></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline;">No.</span></b><b>&#xa0;</b><b><span style="text-decoration: underline;">Description</span></b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_233629.htm" style="-sec-extract:exhibit;">99.1</a></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_233629.htm" style="-sec-extract:exhibit;">Press Release dated March 24, 2021</a></div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_233629.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 7:28:42 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_233629.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 99.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="moleculin-logo_horizresizedf.jpg" src="moleculin-logo_horizresizedf.jpg"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 8:09:09 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"><font style="color:#006699;"><b>Moleculin Biotech, Inc. Reports Financial Results </b></font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><font style="color:#006699;"><b>for the Year Ended December 31, 2020</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">HOUSTON, March&nbsp;24, 2021&nbsp;/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended December 31, 2020 and provided a business update.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><font style="font-family:Times New Roman;font-size:12pt;"><b>Recent Milestones and Accomplishments:</b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Strategy and Events</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:21:28 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">Raised gross proceeds of approximately $81 million through registered equity offering and ATM program in 1Q21 providing runway into&nbsp;2025 based on the Company&#8217;s current R&amp;D spending levels. The Company may expand its R&amp;D expenditures to take advantage of new opportunities within its broad pipeline and/or increase the speed of its clinical trials. At a minimum however, the Company intends for current cash levels to support an operating runway through at least 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Next Generation Anthracycline - Annamycin</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received $1.5 million grant to fund a Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (&#8220;STS&#8221;) lung metastases in Europe</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received FDA IND and ODD for Annamycin against STS; plan to begin a Phase 1b/2 clinical trial in the US for patients after receiving first-line therapy for STS that has metastasized to the lungs</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reached a 2nd dose limiting toxicity (DLT) in March 2021 and plan to establish a maximum tolerable dose (MTD) in our European trial for Annamycin against acute myeloid leukemia (AML); plan to pursue Phase 2 once the recommended Phase 2 dose (RP2D) is established</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Presented animal data at American Society for Hematology showing Annamycin&#8217;s synergistic activity against AML when used in combination with the Ara-C; based on this data&nbsp;we plan a potential Phase 1/2 trial with Annamycin in combination with Ara-C on AML in 2021</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Immune/Transcription Modulators - WP1066 Portfolio</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reported positive interim results in Emory University pediatric brain tumor Phase 1 clinical trial; DIPG patient showed an apparent response in first cohort</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Advanced WP1066 for GBM in adults to fourth and final cohort in dose escalation trial at MD Anderson; notified physician sponsoring trial is leaving MD Anderson; pursuing IND transfer and continuation of research</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received "Rare Pediatric Disease" designation from FDA for WP1066; entitles Moleculin to receive a transferrable Priority Review Voucher upon New Drug Approval for any one of three different brain tumor indications</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Infectious Disease and Metabolism/Glycosylation Inhibitors- WP1122, WP1096 and WP1097 Portfolio</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Multiple positive pre-clinical in-vitro studies on WP122 in its potential ability to address COVID-19</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Positive in vitro results demonstrating the antiviral activity of WP1096 and WP1097 in a range of infectious diseases including: SARS-CoV-2, HIV, Zika and Dengue Fever</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Working to initiate a Phase 1a/1b clinical trial in COVID-19 or a physician-sponsored clinical trial for a cancer indication, or both in 2021</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Anticipated 2021 Milestones</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Potential for 8 clinical trials in 2021, including 3 to be conducted by Moleculin and 5 primarily externally funded and conducted trials; External funding will be relied upon&nbsp;to the extent it is available</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 8:10:51 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;"><b>Management Discussion</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">"We are extremely pleased by the progress we made over the past year despite headwinds from the global COVID-19 pandemic. 2020 proved to be a pivotal year for the Company as we progressed our clinical trials and expanded our product pipeline. Although we are still in the early months of 2021, we are excited to see this momentum build, as we have raised approximately $81&nbsp;million in the first quarter, which will enable us to further pursue our pipeline with expanded pre-clinical and clinical activities, through at least 2023,&#8221; commented Walter Klemp, Chairman and CEO of Moleculin.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:28:14 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;We continue to see tremendous progress and promise across our three primary drug candidates, which have accounted for five Phase 1 clinical trials either completed or under way to date. Our lead candidate Annamycin, our &#8220;Next Generation Anthracycline&#8221; designed to avoid multidrug resistance mechanisms, received an independent assessment last year, which confirmed the absence of cardiotoxicity in patients treated in both our US and European open label and single arm Phase 1/2 clinical trials for acute myeloid leukemia. We were pleased to conclude our US Phase 1/2 clinical trial of Annamycin in AML, and following discussions with the FDA, will focus on establishing a recommended Phase 2 Dose and generating requested safety and efficacy data within our European trial in Poland. In our European trial, we are currently treating patients in the 5th cohort at 240 mg/m2.&nbsp;Dose limiting toxicities relating to liver function have now been noted at this level sufficient to establish an upper limit of dosing.&nbsp;We are planning to amend the protocol for this trial to allow exploration of an intermediate dose level between the 210 mg/m2&nbsp;dose in the fourth cohort and the current 240 mg/m2&nbsp;dose level, in order to establish the maximum tolerated dosage (MTD) and Recommended Phase 2 dose (RP2D), which may be the same.&nbsp;As soon as the RP2D is established, we intend to begin a Phase 2 expansion phase to assess the efficacy of Annamycin as a single agent.&nbsp;In addition, as a result of our preclinical research showing potential synergistic effect from combining Annamycin with Ara-C (a drug commonly used as a single agent and in combination chemotherapy for AML), we also intend to begin the Phase 1 portion of an AML trial using Annamycin in combination with Ara-C.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:29:52 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">While we are pleased by our continued development of Annamycin in AML, we are also excited by the encouraging results observed in Annamycin&#8217;s ability to treat lung metastases. Sponsored research has demonstrated that Annamycin is capable of accumulating in the lungs in animal models at concentration levels up to 34-fold higher than doxorubicin, the current standard of care chemotherapy for a range of lung metastases.&nbsp;This research has also shown that Annamycin has activity in several different lung metastases, including sarcoma, colorectal cancer and triple negative breast cancer. Most recently, we announced that Annamycin demonstrated a potentially significant therapeutic benefit against metastatic osteosarcoma in a preclinical animal study. In this preclinical study, computerized tomography scans showed that animals treated with Annamycin exhibited significant suppression of tumor growth. Further, not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. As of day 130&nbsp;in the trial, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. We have received both Investigational New Drug (&#8220;IND&#8221;) status, and Orphan Drug Designation (&#8220;ODD&#8221;) for Annamycin, allowing us to begin a Phase 1b/2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. To manage the upcoming Phase 1/2 Study in the US, we selected Catalyst Clinical Research as our contract research organization. Our efforts in progressing Annamycin in lung metastasis have also paved the way for&nbsp;a second European trial in 2021, as our license partner recently received a $1.5 million grant from Agencja Bada&#324; Medycznych in Poland to fund a Phase 1b/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases in Europe.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:32:06 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We also continued to drive the clinical development of WP1066, the lead molecule in Moleculin&#8217;s portfolio of immune stimulators and modulators of transcription. WP1066 is currently in two US physician-sponsored Phase 1/2 clinical trials, one at MD Anderson for the treatment of glioblastoma (&#8220;GBM&#8221;) in adults and the second at Emory University for the treatment of pediatric brain tumors. In our Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children being at conducted at the Aflac Cancer &amp; Blood Disorders Center at Children&#8217;s Healthcare of Atlanta, the first cohort of patients was treated with no adverse events related to treatment and the trial has progressed full enrollment of the second cohort at a dose level of 6mg/kg. Notably, within the first cohort, one patient with diffuse intrinsic pontine glioma (&#8220;DIPG&#8221;) showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size; we are particularly encouraged by this apparent response as approximately 200 clinical trials have been conducted in DIPG, and no drug to date has been able to show significant activity in this disease.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:32:51 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In our trial at MD Anderson, WP1066 is in the fourth and final cohort in the dose escalation phase. We were notified during the first quarter of 2021 that the physician sponsoring this trial is leaving MD Anderson. Although we cannot be assured that this trial will continue at MD Anderson after her departure, we have requested that MD Anderson have the IND for this trial transferred into our name to help ensure the potential continuation of this important research. While we are making arrangements to pursue this research in additional physician-sponsored trials, we expect that continued research on WP1066 in adult GBM will be temporarily delayed in 2021.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition to WP1066, we see meaningful opportunity in WP1220, which is an analog of WP1066, in treating cutaneous T-cell lymphoma (&#8220;CTCL&#8221;). The US market for CTCL had estimated sales of $40 million in 2020 and consisted of technologies that are as much as 40 years old. The data from our WP1220 Proof of Concept Trial for the treatment of CTCL, while limited in patient size, was&nbsp;promising; WP1220 demonstrated an objective response rate of 45%, with no adverse events and 55% stable disease, resulting in 100% clinical benefit. Given the tremendous market opportunity and these strong early indications of efficacy, we plan to seek a collaborative partner to support a Phase 2 clinical study of WP1220 in CTCL in 2021.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 1:33:35 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">While we continue to drive the further development of our drugs that are showing meaningful activity in cancer indications, we believe our WP1122 portfolio holds tremendous opportunity for creating long-term shareholder value in the area of infectious disease. In 2020, WP1122 demonstrated its unique mechanism of action and in-vitro activity in numerous preclinical studies and independent research. We believe the preclinical work conducted and under way for WP1122 will support an IND application or its equivalent in other countries for either cancer-related or virus-related clinical trials (or both) during the first half of 2021. Although our initial preclinical focus for the WP1122 program was to help provide a treatment for the growing COVID-19 pandemic, we discovered that two other molecules within our portfolio of antimetabolites displayed significant in vitro antiviral activity against SARS-CoV-2 and other hard to treat viruses. Independent laboratory testing of our drug candidates, WP1096 and WP1097, not only showed significant antiviral activity against SARS-CoV-2, but also showed greater potential against HIV, Zika, and Dengue Fever.<meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/13/2021 8:11:06 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">&nbsp;We caution that the above data is preclinical and there is no assurance that we will see similar results in our planned clinical trials.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Mr. Klemp concluded, &#8220;Our strategy since founding Moleculin has been to deliver long term shareholder value through our &#8216;multiple shots on goal strategy&#8217;. Following our recent capital raise in the first quarter of 2021, we are now optimally positioned to deliver on this strategy, with cash runway through at least 2023, and the potential to <meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/13/2021 8:12:25 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">see 8 clinical trials this year on our drug candidates."</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 8:14:55 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Financial Results for the Year Ended December 31, 2020</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development (&#8220;R&amp;D&#8221;) expense was $12.8 million and $11.0 million for the years ended December 31, 2020 and 2019, respectively. The increase in R&amp;D of $1.8 million was primarily driven by increased clinical trial activity (3 drugs in 4 clinical trials in 2019, versus 3 drugs in 5 clinical trials in 2020), increased costs related to sponsored research agreements, costs related to manufacturing of additional drug product, and two additional employees in R&amp;D headcount.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">General and administrative (&#8220;G&amp;A&#8221;) expense was $6.8 million and $6.3 million for the years ended December 31, 2020 and 2019, respectively. The increase in G&amp;A of $0.5 million was mainly attributable to increased payroll related costs for an additional finance staff, increased stock-based compensation expense, and increased costs for officer's liability insurance being partially offset by reduced travel expenses due to the COVID-19 pandemic.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Net loss for the year ended December 31, 2020 was $17.4 million, which included non-cash gains of $2.3 million on warrants in 2020 as compared to $4.1 million in the prior year and approximately $1.7 million of stock-based compensation expense in 2020 as compared to $1.5 million in 2019.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We believe that our cash resources as of December 31, 2020, along with the additional funding received subsequent to year-end, will be sufficient to meet our projected operating requirements, based on our current use of cash, through at least the year 2023. Such projections are subject to changes in our internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 8:16:51 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For more information about the Company, please visit http://www.moleculin.com.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Forward-Looking Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation,<meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/13/2021 8:16:59 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">&nbsp;our expected cash runway; establishing a recommended Phase 2 Dose for Annamycin in 2021;<meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/13/2021 8:17:52 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">&nbsp;the timing of the commencement and progress of the clinical trials conducted by Moleculin and by third parties; the ability of Moleculin to find a collaborative partner to support a Phase 2 clinical study of WP1220 in CTCL in 2021; and the ability to file for W1122 an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has&nbsp;attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.&nbsp;Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/12/2021 9:03:04 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0"><b>Contacts</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">James Salierno / Carol Ruth</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Ruth Group</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">973-255-8361 / 917-859-0214</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>jsalierno@theruthgroup.com</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>cruth@theruthgroup.com</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>-- Financial Tables Follow--</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34.7%; border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Moleculin Biotech, Inc.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Balance Sheets</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands)</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2020</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2019</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15,173</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,735</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,025</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,749</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,198</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">13,484</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and equipment, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">483</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">316</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intangible assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease right-of-use asset</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">202</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">287</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">25,235</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts payable and accrued expenses and other current liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,570</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,570</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">159</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">276</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warrant liability - long term</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,192</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,818</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,271</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,664</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,760</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15,571</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">25,235</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 23.8%; border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Statements of Operations</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0%; border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="6" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="6" style="vertical-align: bottom; width: 0%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year Ended December&nbsp;31,</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2019</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">12,757</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,013</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative and depreciation</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,985</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,511</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total operating expenses</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,742</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,524</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(19,742</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(17,524</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,346</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,062</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">28</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">13</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">13</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss before taxes</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(17,355</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(13,434</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income tax benefit</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 0.5%; text-align: right;">&nbsp;</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0); vertical-align: middle; width: 0%; text-align: right; padding: 0px;">&nbsp;</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0); vertical-align: middle; width: 4%; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0); vertical-align: middle; width: 0%; padding: 0px;">&nbsp;</td>
			<td style="border-bottom: thin solid rgb(0, 0, 0); vertical-align: middle; width: 4%; padding: 0px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">229</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(17,355</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(13,205</p>
			</td>
			<td style="vertical-align:middle;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1.76</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1.95</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,845,685</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:4.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,786,901</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20210324.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2021 11:20:39 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20210324" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20210324">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210324_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210324_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210324_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20210324/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20210324_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2021 11:20:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20210324/role/statement-document-and-entity-information" xlink:href="mbrx-20210324.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20210324/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20210324_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2021 11:20:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Ex Transition Period</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20210324_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2021 11:20:39 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20210324/role/statement-document-and-entity-information" xlink:href="mbrx-20210324.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20210324/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>moleculin-logo_horizresizedf.jpg
<TEXT>
begin 644 moleculin-logo_horizresizedf.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0"L17AI9@  34T *@    @ !0$2  ,
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M>'!A8VME="!E;F0](G<B/SX _^T .%!H;W1O<VAO<" S+C  .$))300$
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M_C+3AQ)X#5LVS-)XY8'+\:GHK5Y?5>9I+176+KQLE9*5DDDD?P1X.TO]5_I
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MQ.(KU(=I5)R7W.37]?=G2P6#HRYJ-*G"7>,8I_@E_7X]O7 =(4 % !0 4 %
B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>mbrx20210312b_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20210324.xsd" xlink:type="simple"/>
    <context id="d20218K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20218K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20218K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20218K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20218K">2021-03-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20218K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20218K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20218K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20218K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20218K">5300 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20218K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20218K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20218K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20218K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20218K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20218K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20218K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20218K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20218K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20218K">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d20218K">true</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="d20218K">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20218K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20218K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140314841195032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 24, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 24,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity, Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ.#<@V#OX96,'<V/'W?W U!+ P04    " #I.WA2)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ Z3MX4F60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" #I.WA2!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( .D[>%)-AG"H[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .D[>%*97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ Z3MX4CQZ9[);!   _Q   !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .D[>%*?H!OP
ML0(  .(,   -              "  9\,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ Z3MX4I>*NQS     $P(   L              ( !>P\  %]R96QS
M+RYR96QS4$L! A0#%     @ Z3MX4CJJHN=  0  / (   \
M ( !9!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .D[>%(D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( .D[>%)ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20210312b_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20210324/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20210312b_8k.htm">mbrx20210312b_8k.htm</File>
    <File>ex_233629.htm</File>
    <File>mbrx-20210324.xsd</File>
    <File>mbrx-20210324_def.xml</File>
    <File>mbrx-20210324_lab.xml</File>
    <File>mbrx-20210324_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moleculin-logo_horizresizedf.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20210312b_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20210324_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20210312b_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20210324_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20210324_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20210324.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20210324",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20210312b_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20210324/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20210312b_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity, Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210324/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-21-006941-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-006941-xbrl.zip
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MT'7G4.Z/*0CK &L&"E@ME)$D-R %G\U'7^SIT;OS9\AN%/!2G&M".,NJ$(
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M.A[MW]XVW4=_[M3>T+I)]S%8'3F!_<N]H4DB&KD_(^,&Q"V)@D=G =8G@%.
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MP:\H?#FFAY#C"U% 1\KFRJT0$N!9_)7!K7"5YD.$@9#!&@Z!2']JP"(6N;T
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M)QVO*6-?1:*N=M:WUK>N\*WKX.J^X3(VKJX_YO%(,/S(9<(N>)@);&N\G#V
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M")7?>;^\UDT8TFZRJ<+P^1=02P,$%     @ Z3MX4@S4TW3X!   #"\  !4
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MEWW%1X%7;2+(OLK#P.(^\5+]7[3);G]^/MY7?]3_6<L[_P-02P,$%     @
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MN[U<MF9VN2Q*=9$0;F%:I[,1*OMS0,3.10S$UNUV%\G^OUKL^0]02P,$%
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ML'PS\;UD#8-.:IQ8I_D7:E?K9N>W7\X+UEDU ,5=/B,NP--L'&/G8[MS:C,
MRU/V..-Z8KHO<0HF&T_W;%+7[/C(0B]!BD=@3Y@WQK9M)/TIN"Q0(#D6#>K%
MN,7K<+]_8XP7H^5N530FW/X"6*@!FV&7A-&)BK>AOX A=_U;4@4-DL+@W/@(
M(WU*#R) LU+<<U!%RH= 3.>N8A['G.(N(<#B(1@M]<QH@C]$>EA< ]* 7#?J
M^DX 1K]E/#;R741.\ZAS$U1@!8!QHA9P#NB'M??<XQ)C:-O#)>9A;5DW"V9(
M]5'ET-[OV]X/?:7\:82D=&*>/6TQNFV8W]C?#WW?'3(T%V1TD8SG_Y)"H852
MB3[WHGHV(+V5STJEZMU@'JHSFH.8DY-@-I?!G P53;TW1SV7"B>1T9*U]C&/
MXT2!XJC;"K+6&30N>U HYDT$W%T_/Z*9^X_32M]WA8VR\L;7&&BH]GU )>L)
M,(UF;.O#*C'#*B14TEJ$"613(:6\&4(>=)+4R8WDY"5T!T(?*5)8E]W1B&J@
M>W6#$PT[,?-!O[%*CE'(#H\>IZD0]J"K>W35#H(YET^IL2(W2EG[<1I#6(N
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MX[JMK^UB&B B I*V&?<RD8M&_JHAL WF-*UX2J^V'4&.ARR;/X;HOZ.5\^!
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M;\+#[?!.!O+/0WV3![84,PJ)]W:SSUG_'LSTNQ7-(/Q6G"]^+Q2+IX4R_5Z
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MZX:P>TBMJ>]4V/B7B'WZ'>*U_P=02P,$%     @ Z3MX4OPE9O]00   BTL
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MG2:RO,<8*;P7L=*/NK10SI=LR/E+L]=1;(]OFY-W+'C_#<0L\0B:REZ0F96
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MGN>$JWVL#J;_4$]./SZ=@*V/GM  GMM3/B8G.0].\K8I9T5^OB5=,_7A=D!
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MZD5QQ2\B8BJR4E*-]ZM_ENT!-\V/;=Q;:I*_>HDM-C]?: KXJN%=1H#RPCW
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MTSD:0&DE5,(BQ<B_.+!IDE+]ZSGQ0)@XWL:KKG+;G /$C#BT\JC*5^5!/B;
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M9GD\33-B/$,M.+,TF?,4>@)F$*R&>[B^3+F$>'S&WW]?U9"-^1J2+Y])=\K
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M4$L! A0#%     @ Z3MX4M:TT\F% P  DPX  !$              ( !V24
M &UB<G@M,C R,3 S,C0N>'-D4$L! A0#%     @ Z3MX4@S4TW3X!   #"\
M !4              ( !C2D  &UB<G@M,C R,3 S,C1?9&5F+GAM;%!+ 0(4
M Q0    ( .D[>%("L>Q^) 8   0_   5              "  ;@N  !M8G)X
M+3(P,C$P,S(T7VQA8BYX;6Q02P$"% ,4    " #I.WA2N?$/)Y,$  #5+P
M%0              @ $/-0  ;6)R>"TR,#(Q,#,R-%]P<F4N>&UL4$L! A0#
M%     @ Z3MX4DOP:LBF#@  ]&(  !0              ( !U3D  &UB<G@R
M,#(Q,#,Q,F)?.&LN:'1M4$L! A0#%     @ Z3MX4OPE9O]00   BTL  "
M             ( !K4@  &UO;&5C=6QI;BUL;V=O7VAO<FEZ<F5S:7IE9&8N
9:G!G4$L%!@     '  < TP$  #N)      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
